Stockreport

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

BioRestorative Therapies, Inc.  (BRTX) 
NASDAQ:AMEX Investor Relations: biorestorative.com/content/investor-relations
PDF - Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 1 [Read more]